Live Breaking News & Updates on Junshi

Stay informed with the latest breaking news from Junshi on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Junshi and stay connected to the pulse of your community

Coherus again axes staff, with 30% of roles on chopping block amid 'sharpened focus' on cancer drugs

Coherus again axes staff, with 30% of roles on chopping block amid 'sharpened focus' on cancer drugs
fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.

Canada , California , United-states , China , Junshi , Anhui , Canadian , Chinese , Paul-reider , Coherus-biosciences , Amgen-neulasta ,

Garsorasib Plus Cetuximab Shows Early Efficacy in Heavily Pretreated KRAS G12C+ CRC

The combination of garsorasib and cetuximab elicited responses and was found to be well tolerated in heavily pretreated patients with KRAS G12C–mutated colorectal cancer.

Junshi , Anhui , China , Guangzhou , Guangdong , Rui-hua-xu , Keymed-bioscience , Astrazeneca , Bristol-myers-squibb , Clinical-research , Sun-yat-sen-university-cancer-center , Colorectal-cancer

Fierce Pharma Asia—Merck KGaA and Hengrui's PARP deal; Novartis and Takeda's employee dispute; toripalimab's FDA nod

Fierce Pharma Asia—Merck KGaA and Hengrui's PARP deal; Novartis and Takeda's employee dispute; toripalimab's FDA nod
fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.

China , Junshi , Anhui , Japan , Japanese , Coherus-biosciences , Daiichi-sankyo , Astrazeneca-lynparza , Denny-lanfear , Merck-kga , Merck-co , Merck-kgaa

Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial

Objective To assess the efficacy and safety of pyrotinib (an irreversible pan-HER (human epidermal growth factor receptor) inhibitor), trastuzumab, and docetaxel compared with placebo, trastuzumab, and docetaxel for untreated HER2 positive metastatic breast cancer.

Design Randomised, double blind, placebo controlled, multicentre, phase 3 trial.

Setting 40 centres in China between 6 May 2019 and 17 January 2022.

Participants 590 female patients (median age 52 (interquartile range 46-58) years) with untreated HER2 positive metastatic breast cancer.

Interventions Eligible patients were randomised 1:1 to receive either oral pyrotinib (400 mg once daily) or placebo, both combined with intravenous trastuzumab (8 mg/kg in cycle 1 and 6 mg/kg in subsequent cycles) and docetaxel (75 mg/m2) on day 1 of each 21 day cycle. Randomisation was stratified by treatment history of trastuzumab in the (neo)adjuvant setting and hormone receptor status. Patients, investigators, and the sponsor’s study team were masked to treatment assignment.

Main outcome measures The primary endpoint was progression-free survival as assessed by the investigator.

Results Of the 590 randomised patients, 297 received pyrotinib, trastuzumab, and docetaxel treatment (pyrotinib group), and 293 received placebo, trastuzumab, and docetaxel treatment (placebo group). At data cut-off on 25 May 2022, the median follow-up was 15.5 months. The median progression-free survival according to the investigator was significantly longer in the pyrotinib group than in the placebo group (24.3 (95% confidence interval 19.1 to 33.0) months versus 10.4 (9.3 to 12.3) months; hazard ratio 0.41 (95% confidence interval 0.32 to 0.53); one sided P<0.001). Treatment related adverse events of grade 3 or higher were reported in 267 (90%) of the 297 patients in the pyrotinib group and 224 (76%) of the 293 patients in the placebo group. No treatment related deaths occurred in the pyrotinib group, and one (<1%; diabetic hyperosmolar coma) treatment related death occurred in the placebo group. Survival and toxicities are still under assessment with longer follow-up.

Conclusions Pyrotinib, trastuzumab, and docetaxel showed superiority by significantly improving progression-free survival compared with placebo, trastuzumab, and docetaxel in patients with untreated HER2 positive metastatic breast cancer. The toxicity was manageable. The findings support this dual anti-HER2 regimen as an alternative first line treatment option in this patient population.

Trial registration ClinicalTrials.gov [NCT03863223][1].

Reasonable requests for data sharing should be made to the corresponding author and will be handled in line with the data access and sharing policy of the Human Genetic Resource Administration of China.

[1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT03863223&atom=%2Fbmj%2F383%2Fbmj-2023-076065.atom

China , Junshi , Anhui , Qilu , Gansu , Xuanzhu , Zhejiang , Helsinki , Eteläuomen-läi , Finland , Chinese , Pconclusions-pyrotinib

Coherus rejects 'heavily discounted' pricing on Loqtorzi, the first China-made PD-1 drug to win FDA nod

Coherus rejects 'heavily discounted' pricing on Loqtorzi, the first China-made PD-1 drug to win FDA nod
fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.

Junshi , Anhui , China , Canada , Bristol-myers-squibb-opdivo , Eli-lilly , Coheru-lanfear , Denny-lanfear , Daina-graybosch , Coherus-biosciences , Paul-reider , Novartis

Coherus BioSciences, Inc. (NASDAQ:CHRS) Q2 2023 Earnings Call Transcript

Operator: Good day and thank you for standing by. Welcome to the Coherus Biosciences Second Quarter 2023 Conference Call. At this time all participants are in a listen-only mode.

United-states , Junshi , Anhui , China , American , Chris-schott , Theresa-lavallee , Douglas-tsao , Mcdavid-stilwell , Balaji-prasad , Mark-cuban , Marek-ciszewski

FDA flags issues at Coherus partner's China plant for cancer drug

Coherus BioSciences Inc said on Wednesday that the U.S. Food and Drug Administration had flagged three observations at its partner's manufacturing site in China when the agency was conducting... | May 31, 2023

Junshi , Anhui , China , Bengaluru , Karnataka , India , Pooja-desai , Raghav-mahobe , Bhanvi-satija , Shanghai-junshi-biosciences-co-ltd , Rashmi-aich

FDA flags issues at Coherus partner's China plant for cancer drug

(Reuters) -Coherus BioSciences Inc said on Wednesday the U.S. Food and Drug Administration (FDA) had flagged three observations at its partner's ...

China , Bengaluru , Karnataka , India , Junshi , Anhui , Pooja-desai , Raghav-mahobe , Bhanvi-satija , Coherus-biosciences-inc , Shanghai-junshi-biosciences-co-ltd , Reuters

FDA flags issues at Coherus partner's China plant for cancer drug

(Reuters) -Coherus BioSciences Inc said on Wednesday the U.S. Food and Drug Administration (FDA) had flagged three observations at its partner's ...

Junshi , Anhui , China , Bengaluru , Karnataka , India , Raghav-mahobe , Pooja-desai , Bhanvi-satija , Drug-administration , Shanghai-junshi-biosciences-co-ltd , Reuters

Junshi Biosciences Announces Collaboration with Dr. Reddy's to Develop and Commercialize Toripalimab in 21 Countries

SHANGHAI, China, May 07, 2023 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences", HKEX: 1877; SSE: 688180) announced a collaboration with Dr. Reddy's Laboratories Limited ("Dr.

India , United-kingdom , United-states , Brazil , Bombay , Maharashtra , China , Australia , Uzbekistan , Peru , New-zealand , Panama